Search results
Results from the WOW.Com Content Network
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois.It is ranked sixth on the list of largest biomedical companies by revenue.In 2023, the company's seat in Forbes Global 2000 was 74, [2] and rank 89 on the 2024 list. [3]
Investing.com - AbbVie (NYSE:ABBV) reported third quarter earnings that beat analyst's expectations on Friday and revenue that topped forecasts.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity. [6] The merger is expected to close in mid-2015. [7]
Total revenue was down 3% on a year-over-year basis in the quarter. ZoomInfo ended the quarter with 1,809 customers generating $100,000 or more in annual contract value, marking an increase of 12 ...
ZoomInfo Technologies Inc., is a software and data company which provides data for companies and business individuals. [ 2 ] [ 3 ] [ 4 ] Their main product is a commercial search-engine , specialized in contact and business information.
In June 2019, U.S. pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for $63 billion, [7] which would return Allergan to the U.S. for tax purposes. [8] On the announcement of the transaction, Abbvie disclosed that its 2019 net effective tax rate was 9%, but that post the acquisition, the Group's effective ...
On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) [21] worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. [22]